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Abstract: The cell cycle is an important cellular process whereby the cell attempts to replicate its
genome in an error-free manner. As such, mechanisms must exist for the cell cycle to respond to
stress signals such as those elicited by hypoxia or reduced oxygen availability. This review focuses
on the role of transcriptional and post-transcriptional mechanisms initiated in hypoxia that interface
with cell cycle control. In addition, we discuss how the cell cycle can alter the hypoxia response.
Overall, the cellular response to hypoxia and the cell cycle are linked through a variety of mechanisms,
allowing cells to respond to hypoxia in a manner that ensures survival and minimal errors throughout
cell division.
Keywords: hypoxia; cell cycle; HIF; PHDs; 2-OGDs; mitosis
1. Introduction
The cell cycle is a process through which cells faithfully replicate their genetic material.
Strict control over its progression is therefore needed to avoid errors that could result in cell
death or cell malignancy. As such, understanding how the cell cycle is affected by external
and internal stresses is of the utmost importance, in particular, the stress caused by hypoxia,
or reduced oxygen availability. Hypoxia is an important factor in embryo development, but
is also present in numerous pathological settings such as ischaemic events and cancer [1].
Oxygen is fundamental for both energy homeostasis and cellular viability, therefore, to
deal with such stresses, cells possess complex response mechanisms that aim at restoring
oxygen homeostasis. In this review, we highlight how hypoxia sensing and signalling
pathways interface with the cell cycle, in addition to how the cell cycle affects the hypoxia
sensing and response components in mammalian cells.
2. Hypoxia Signalling Pathway
In cells, oxygen is sensed by a class of 2-oxoglutarate, iron-dependent dioxygenases
(2-OGD); the most recognized of which are the prolyl-hydroxylases (PHDs). These are
instrumental in the signalling cascade initiated in response to a reduction in oxygen, which
ultimately results in the activation of the hypoxia-inducible factor (HIF) transcription
factor family. HIFs are heterodimers corresponding to a HIF-α (alpha) and HIF-1β (beta)
subunit [2], while the PHDs present three isoforms (PHD1, PHD2, and PHD3) and possess
a low affinity for oxygen so that any small deviation from normal oxygen concentrations
will result in their enzymatic inactivation [3]. Under normal oxygen concentrations, the
PHDs hydroxylate specific proline residues in the oxygen-dependent degradation domain
(ODD) of HIF-α. This post-translational modification increases the binding affinity of the
von Hippel-Lindau (VHL) protein, which acts as part of the recognition complex for the
E3 ligase comprising of Elongin B/C, Cullin2, and RBX1 [4]. This complex ubiquitinates
HIF-α, which marks the protein for proteasomal degradation. In the absence of either
oxygen, iron (Fe2+), or 2-oxoglutarate (2-OG), the PHDs cannot function and the ability
Int. J. Mol. Sci. 2021, 22, 4874. https://doi.org/10.3390/ijms22094874 https://www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2021, 22, 4874 2 of 15
of VHL to promote ubiquitination of HIF is reduced, which results in the stabilization of
HIF-α. Upon stabilization, and in combination with its binding partner HIF-1β, a HIF-1α-β
heterodimer promotes the transactivation of a variety of target genes in response to reduced
oxygen concentrations (for a recent review on HIF-dependent genes see [5]). Notably, it
is important to highlight that, in addition to HIF, further transcription factors are also
activated by hypoxia. These include Myc, p53, AP-1, Sp1, and NF-κB [6] (Figure 1).
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protein kinases (MAPK) activate AP-1 subunits (c-jun/c-fos) in response to hypoxia. Activation of AP-1 heterodimers
predominantly exert their effects in cooperation with additional transcription factors including NFκB and HIF-1α to activate
common target genes including regulation of cell proliferation and apoptosis. NFκB likewise regulates HIF-1α transcription.
Additional important 2-OGD enzymes, with links to hypoxia sensing and response,
are JmjC-histone demethylases and TET DNA demethylases. Moreover, other JmjC-
hydroxylases and RNA demethylases such as FTO and ALKBH5 are lik wise potential
contributors to the hypoxia re ponse. However, additional work is ne ded to ntify
their true involvement. Int restingly, all of these afor mentioned enzymes also have the
potential to either directly or in irectly interface with the cell cycle (Figure 1).
3. Cell Cycle Overview
The cell cycl ca be divided into two m i stages: interphase n cell division
(Figure 2). Interphase is where cells spend the majority of the time and can be sub ivide
into Gap1 (G1), S (DNA ynth sis), and Gap2 (G2) phases; whereby following the G2-phase
the cells enter mitosis (M) (cell division). Here, the duplicated DNA is distributed equally
into two daughter cells, which then enter a new cell cycle (Figure 2). In G1, individual cells
grow and their cellular content is duplicated, while in S-phase, the DNA is replicated, then
in G2, the cell undergoes further growth and prepares for cellular division [7]. Finally, in
mitosis, the cell divides its contents into two equal daughter cells. Here, depending on the
cell type, cells will either enter another G1 stage or enter quiescence (also known as G0),
whereby the cell exits the cell cycle and stops dividing [8].
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Figure 2. The mammalian cell cycle phases. The cell cycle is divided into two main phases: interphase
that includes G1, S, and G2, and mitosis. Each of these stages is associated with a CDK/Cyclin pair,
controlling the progression of the cell cycle.
The progression through the cell cycle is regulated by serine/threonine protein kinases
known as cyclin-dependent kinases (CDKs), alongside their partner proteins, cyclins
(Figure 2). However, CDK-independent roles have also been described for the cyclins
in t e reg latio of a o tosis, differentiation, DNA repair, and metabolism reviewed
in [9,10]. CDK-cyclin complexes phosphorylate specific substrates i eac ase f t e cell
cycle, drivin the transition to the next phase. e activatio of the C depends on the
ass ci ti it t e corres i re l t r c cli ; t eref re, the levels of each cyclin
fluctuate during the cell cy le. This o cillation f the cyclin leve s is regulated through their
targeted degra ation by different E3 ligase complexes in response to ignalling pathw ys
such a growth factor nd oncoge e activation [11]. CDK activity is also regulated by
phosphorylation and by association with CDK-cyclin inhibitors such as p21 and p27, while
the dysregulation of CDK activity is a common feature in many cancers [12,13].
ell cycle progressio is therefore a tightly regulated process that includes several
c ec i t t t are i perati ri cell divisi t ens re the correct segregation of
the ge etic aterial bet een daughter cel s. rt er ore, as the cel cycle is also a highly
e anding and e ergy-consu ing proces , it follows that the oxygen-sensing system can
irectly impact cell cycle progression [14]. Indeed, key players in the hypoxia response are
involved in the regulation of essential components during each p ase of the cell cycle, at
each of the transcriptional and protein stability levels, alongside localization and/or activity.
Hence, oxygen deprivation or hypoxia must impact normal cell cycle progression [14]. In
this review, we provide examples of how cell cycle progression in normal and cancer cells
can be affected in response to oxygen levels, focusing on the molecular interplay between
hypoxia and known cell cycle regulators.
4. Hypoxia Mediated Transcriptional Effects on Cell Cycle Components
Hypoxia plays a central role in diverse aspects of cancer biology as a hypoxic mi-
croenvironment is prevalent in solid tumours. It is known that oxygen levels regulate cell
proliferation and that depending on the cell type, hypoxia can inhibit cell proliferation
by inducing cell cycle arrest [15–17]. However, tumour cells often adapt to survive in
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such hypoxic conditions. This adaptation is partially promoted by the essential role HIF
plays in the transcriptional regulation of genes associated with angiogenesis, apoptosis,
cell proliferation, and energy metabolism [2]. HIF-dependent activation of these genes
provides tumour cells with an adaptive advantage over normal cells during periods of
hypoxic stress.
The Myc transcription factor, which is also associated with cell proliferation, is simi-
larly overexpressed in various cancer types [18]. Myc is known to repress the expression
of the CDK cyclin inhibitors p21 and p27 [18]. In hypoxia, the expression of p21 and
p27 is induced in a HIF-1α dependent manner, partially by displacing Myc from their
promoters [15]. Interestingly, HIF-2α cooperates with Myc and promotes cell proliferation
in renal clear cell carcinomas (RCC) and other cell types [19]. In RCC, HIF-2α is also known
to induce Cyclin D1 via its binding to an enhancer site [20] (Figure 3). The effects of HIF-2α
on cell cycle control in RCC cells have become even clearer following data derived from
treatments with a specific HIF-2α inhibitor (PT2399), in which the cell cycle was identified
as the main signature controlled by HIF-2α [21,22].
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activator of the CDK-inhibitor, p21 [41]. Additionally, p21 expression can be further in-
creased by the Formin-2 (FMN2) protein, which is a component in the p14ARF tumour 
suppressor pathway [42]. In this study, FMN2 was shown to increase with hypoxia stim-
ulation via an NF-κB-dependent mechanism [42]. Moreover, several additional studies 
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suppression of E2F-responsive gene expression [45]. In contrast, E2F1 and NF-κB interac-
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Figure 3. Hypoxia-induced transcriptional effects on the cell cycle. HIFs and NF-κB control the expression of a number of
important components of the cell cycle machinery and control mechanisms. HCC: Hepatocellular carcinoma.
The mitotic kinase—Aurora A (AURKA)—also has an important role in mitotic pro-
gression and has been related to oncogenic phenotypes [23]. AURKA is overexpressed in a
variety of different tumours and has been implicated in cell transformation and centrosome
amplification [24,25]. In hepatocellular carcinomas (HCC), the increased levels of AUR A
do not always correlate with gene amplification [26]. Interestingly, AURKA was shown to
be induced by hypoxia in a HIF-1α dependent man er in HepG2 cells [27] as HIF-1α binds
to the AURKA promoter and upregulates its transcription, l ading to an increas in cell pro-
liferati [27]. This study proposed that AURKA might be involv d in the hypoxia-induc d
proliferation of HCC tumours [27] (Figure 3). In this tumour type, hypoxia induction of
HIF-1α and AURKA might be inv lved in promoting HCC proliferation [27]. However, in
breast cancer cells (MCF-7, MDA-MB-231, and SK-Br3), microa ray a alysis in response
to hypoxia illustrates that hypoxia d wnregulates AURKA [28]. In this study, the a th rs
demon trated t at hypoxia downregulated AURKA via a HIF-1α dependent mech nis ,
suggesting that HIF-1α is a negativ regulator of AURKA in br ast cancer tumours [28].
These studies highlight the cell-specific nature of HIF’s function i cell cycle regulation.
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Cell division cycle-associated protein 2 (CDCA2) has similarly been shown to be a
target of the hypoxia pathway [29]. Analyses of publicly available ChIP-Seq and RNA-Seq
datasets demonstrate that CDCA2 is induced in hypoxia and is important for the con-
trol of proliferation in prostate cancer cells. The intracellular signal transducer protein,
SMAD3, binds to the CDCA2 promoter and recruits HIF-1α. HIF-1α/SMAD3 then medi-
ates the transcriptional regulation of CDCA2 in hypoxic tumours, leading to cancer cell
proliferation [29].
HIF’s control of the cell cycle is also mediated by its ability to induce a variety of
microRNAs and long non-coding RNAs; this aspect was reviewed in [14,30].
Among all known hypoxia-stimulated transcription factors, the importance of NF-κB
has been identified in a wide range of signalling systems, alongside its association with
many different diseases. In contrast to its well-established role in immune and inflamma-
tory responses, NF-κB activity is also involved in apoptosis, carcinogenic transformation,
and cell cycle transition [31]. The NF-κB family consists of five distinct members, which
include RelA (p65), RelB, c-Rel, NF-κB1 (p105/p50), and NF-κB2 (p100/p52), all of which
share a conserved Rel homology domain [31]. Hypoxia activation of NF-κB occurs via sev-
eral mechanisms, although some of the details still require further investigation. Hypoxia
has been shown to control NF-κB via the action of PHDs and FIH [32–34], and requires the
involvement of calcium/calmodulin-dependent kinase II (CAMKII), transforming growth
factor kinase 1 (TAK1) and IκB kinase (IKK) [35–37].
NF-κB has several target genes identified with a role in cell cycle progression (re-
viewed in detail [31]). Ultimately, cyclin D1 provides a predominant link between NF-κB
and cell cycle progression (Figure 3). Cyclin D1, in association with CDK4 and CDK6,
promotes G1/S phase transition through CDK-dependent phosphorylation of retinoblas-
toma protein (pRB) [38]. This phosphorylation event releases the transcription factor E2F,
which is required for the activation of S-phase-specific genes, although several studies have
conversely reported that NF-κB can itself induce cell cycle arrest [39]. Overexpression of
RelA has been shown to arrest cells at G1/S-phase transition [40]. c-Rel overexpression
leads to cell cycle arrest through p53 protein stabilization, an important upstream activator
of the CDK-inhibitor, p21 [41]. Additionally, p21 expression can be further increased by
the Formin-2 (FMN2) protein, which is a component in the p14ARF tumour suppressor
pathway [42]. In this study, FMN2 was shown to increase with hypoxia stimulation via an
NF-κB-dependent mechanism [42]. Moreover, several additional studies have shown that
NF-κB can be activated by a hypoxic environment [35,36,43,44].
Finally, a physical and functional interaction exists between the IKK/NF-κB signalling
pathway and the cell cycle regulatory proteins of the E2F family that controls S-phase entry,
which suggests that NF-κB plays a functional role in controlling cell division [45,46]. Indeed,
direct phosphorylation of E2F by IKKα and IKKβ resulted in the nuclear accumulation and
enhanced DNA binding of the E2F4/p130 repressor complex, which led to the suppression
of E2F-responsive gene expression [45]. In contrast, E2F1 and NF-κB interactions were
shown to control the timing of cell proliferation [46] (Figure 3). Despite all of these links
between NF-κB and cell cycle regulation, a more systematic and mechanistic analysis of
how NF-κB controls the cell cycle in hypoxia is needed.
5. Hypoxia Transcriptional-Independent Effects on Cell Cycle Components
Apart from transcription, hypoxia can alter a variety of other processes such as
translation and post-translational modifications. As such, non-transcriptional mechanisms
are also involved in hypoxia-induced cell cycle alterations (Figure 4).
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of cell types including, cancer cell lines, haematopoietic stem cells, fibroblasts, and lym-
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DNA replication. In addition, PHD1 and PHD3 have non-HIF targets involved in the control of the cell cycle.
5.1. Non-Transcriptional Role for HIF-1α
A non-transcriptional mechanism through which cell cycle progression is inhibited
involves HIF-1α regulation of DNA helicase loading. During G1, under normal conditions,
the MCM proteins assemble into a hexamer, poised in an inactive yet loaded state, by both
Cdc6 and Cdt1 [47]. When transitioning from G1 into the S-phase, CDK2 catalyses the
phosphorylation of the complex and promotes the nuclear export of the inhibitory Cdc6,
therefore allowing for Cdc7-mediated phosphorylation of the MCM complex and the sub-
sequent activation of DNA replication [48,49]. Upon hypoxic stress, HIF-1α interacts with
Cdc6 to promote nuclear localization with the MCM complex [50]; while HIF-1α-bound
Cdc6 increases MCM association with chromatin, t e presence of HIF-1α prevents Cdc7
from phosphorylating the complex [51]. Consequently, replication origin firing is blocked
as Cdc45 and DNA polymerase α cannot be recruited. Subsequently, HIF-dependent
blocking of DNA replication and pr liferation was observed across a variety of cell types
including, cancer cell lines, haematopoietic stem cells, fibroblasts, and lymphocytes [51–53].
While he regulatory binding of HIF-1α to protein complexes inhibits the proliferative
signals in some tissues, sev ral cance cells possess the capacity to proliferat even under
hypoxic conditions [54].
5.2. HIF-Independent PHD-Dependent Roles in Cell Cycle
Given that oxygen is s nse by the 2-OGDs, it is likely that other aspects of the cell
cycle could be regulated independently of HIF activity. This is definitely the case for the
PHDs, whose association to cell cycle control has been best documented [14]. Of note, in
addition to requiring oxygen as a co-substrate, their functional catalytic activity further
requires the presence of additional co-factors: 2-oxoglutarate and iron [55,56]. PHDs can
additionally monitor amino acid concentrations [57], cellular nutrients [58], and act as
metabolic sensors to detect defects in metabolic pathways such as the tricarboxylic acid
(TCA) cycle [59]. As such, PHD activity is similarly inhibited following an accumulation of
metabolite intermediates due to mutations in the metabolic enzymes: fumarate hydratase
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(FH), succinate dehydrogenase (SDH), and isocitrate dehydrogenase 1 and 2 (IDH1 and
IDH2) [60].
Whilst still controversial within the hypoxia field [61,62], over the last decade, emerg-
ing studies have highlighted alternative roles for PHDs, identifying substrates, in addition
to HIF-α, which are involved in a myriad of different pathways and regulated through
PHD-hydroxylation [3].
Interestingly, within these emerging substrates, both PHD1 and PHD3 have been
shown to play critical roles in response to oxygen depletion: first, in the regulation of
proteins involved in the DNA damage response, and second, in centrosome biogene-
sis [63,64]. These two processes are critical in regulating the cell cycle. In cultured human
cells, Moser et al. (2013) showed that variations in oxygen concentration altered the mitotic
cell cycle progression through PHD1-mediated hydroxylation of the centrosomal protein
192 (Cep192) [63]. Cep192 acts as a large scaffold protein in human centrosomes and its
expression is required for centrosomal duplication and maturation in addition to centriole
duplication [65–67]. The authors discovered that after two and four hours in 1% O2, the
protein levels of Cep192 stabilised to those comparable to HIF-1α in U2OS cells. Cep192
undergoes a post-translational modification, whereby in normoxia, PHD1 hydroxylates
proline 1717, which promotes Cep192 proteasomal degradation. However, unlike HIF-α,
which is degraded through the VHL pathway, PHD1-mediated hydroxylation of Cep192
stimulates the recruitment of the SCF(Skp2) E3-ligase complex, which mediates the ubiqui-
tination that promotes Cep192 proteasomal degradation. The study by Moser et al. (2013)
ultimately provided a mechanistic link between PHD activity and the direct regulation
of the cell cycle, highlighting the role that oxygen availability plays on the processes of
centrosome duplication and maturation, in addition to centriole duplication through the
modulation of Cep192 stability.
Alongside Cep192, PHD1 has likewise been shown to modulate protein levels of the
G1 cyclin—cyclin D1 [68]. Targeted-hydroxylation of the Forkhead Box O3A (FOXO3A)
transcription factor at proline residues 426 and 437 in normoxia was revealed to destabilise
its interaction with the deubiquitinase USP9x and promote FOXO3a degradation, a process
that leads to an accumulation of cyclin D1 [68]. Moreover, PHD1 regulation of cyclin D1
has further been demonstrated in breast cancer cells [69], whereupon inactivation of the
Egln2 (Phd1) gene, cyclin D1 levels, and mammary gland cell proliferation decreased.
Interestingly, it is not solely PHD1 that has been found to be involved in the reg-
ulation of cell cycle components. However, while PHD2 represents the most abundant
PHD isoform, it has currently not been shown to interact with any validated cell cycle
machinery components. However, as the predominant regulator in the hypoxia pathway,
many studies have focused on the role PHD2 plays in various tumour types. Percy et al.
(2006) proposed that PHD2 functions as a tumour suppressor [70]. Tao et al. (2016) re-
vealed that PHD2 inhibited cell proliferation due to cell cycle arrest at the G1/S-phase
transition [71]. Additionally, the authors demonstrated that the arrest in the cell cycle
was facilitated by negative regulation of cyclin D1 in a PHD2 hydroxylation-dependent
manner [71]. These findings correlate with previously published data indicating that PHD2
can act in a tumour suppressor role in cancer cells [72–74]. However, several other studies
have shown that downregulation of PHD2 in tumour cells corresponds to a reduction in
tumour growth [75,76]. This indicates that PHD2 can act as a tumour promoter or tumour
suppressor, depending on cell and/or tissue type.
PHD3 has similarly been suggested to function as a tumour suppressor, whereby its
expression induced apoptosis [77] and inhibited angiogenesis and tumour growth [78].
Equally, PHD3 is required to induce apoptosis and inhibit tumour growth in vivo [79].
Moreover, cell cycle distribution analysis revealed that the overexpression of PHD3, in
conjunction with radiation in pancreatic cancer cells, results in a reduced S-phase and a
lengthened G2/M phase [80].
p53 has an important role in cancer biology as an important regulator of the cell cycle
and it is also activated in hypoxia [81]. PHD3 regulates p53 stability by hydroxylation
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at proline 359 [82]. This modification increases p53 association with USP7 and USP10
deubiquitinases, leading to reduced ubiquitination and enhanced stabilisation [82].
5.3. Hydroxylation and Phosphorylation Interplay
Proline hydroxylation usually acts as a docking site for protein–protein interactions,
best exemplified by the HIF-1α/VHL association [83]. As such, it is possible that apart
from ubiquitin ligases, proline hydroxylation could act as a binding site for other pro-
teins including kinases or phosphatases (Figure 5). The AKT kinase is a key player in
oncogenesis [84]. Guo et al. (2016) demonstrated that PHD2 mediated hydroxylation of
AKT promotes the binding of this kinase to the VHL ubiquitin ligase. Interestingly, this
interaction does not target AKT for degradation, but instead leads to AKT inactivation
through PP2A phosphatase-mediated dephosphorylation. It was suggested that in hypoxic
microenvironments or in cells lacking a functional VHL protein, AKT is hyper-activated,
which promotes cancer cell survival [85]. These examples demonstrate that hydroxylation
mediated by PHDs not only targets proteins directly for degradation, but also plays an
important role in regulating protein–protein interactions.
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Figure 5. PHD-mediated hydroxylati i se activity. Hydroxylation of kinases can lead
to induction of autophosphorylation, recruitment of phosphatases, or even other kinases. This will result in changes to
kinase activity.
Another such example sug ests an interplay betwe n two protein modifications as
proline hydroxylation and phosphorylation have be n recently reported to play a role in
cell cycle progres ion [86]. In a study of the DYRK1 kinase, a conserved proline located in
the kinase domain was hown to be hydroxylated by PHD1 [86]. Autophosphorylation i a
specifi tyrosine residue is cr tical for the enzymatic activity of DYRK1. Interestingly, PHD1
mediated hydroxylati n of DYRK1 takes place during t anslation, but before ty osine
phosphorylation occurs. F thermore, proline hydrox lation is important for the tumour
suppre sion activity of DYRK1 toward the regulation of VHL E3 ligase activity and hence,
t stability of VHL substrates cri ical for cell cycle progression such as HIF-2α, AURKA,
and cyclin D1. In co clusion, Lee et al. (2020) showed that DYRK1 hydroxylation precedes
the phosphorylation/activation of the ki ase, which is required for VHL tumour suppres-
sion function [86,87]. Since PHD1 hydroxylates the proline within a conserved kinase
domain (CMGC), the authors suggest that proline hydroxylation could be an essential
mechanism in the catalytic activation of all eukaryotic CMGC kinases [86]. CMGC kinases
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have crucial roles in controlling the cell cycle and include CDKs, MAPK, and CDK-like
kinases [88]. Unbiased proteomic studies are therefore needed to investigate the possibility
that proline hydroxylation has a global effect on protein phosphorylation.
6. How the Cell Cycle Controls the Hypoxia Response
Since the cell cycle is a highly coordinated process and considering the published
links to the regulatory roles of both HIF and the PHDs within the cell cycle, it could be
speculated that either HIF and/or the PHDs would themselves be subject to regulatory
control by the cell cycle. Indeed, evidence of such control already exists.
6.1. Cell Cycle Components-Mediated Control of HIFs
In addition to its regulatory dioxygenases, several kinases directly involved in the cell
cycle have similarly been shown to directly phosphorylate and regulate HIF-α [89].
Indeed, CDK1 has been shown to directly phosphorylate HIF-1α and promote HIF
stabilization and activity [90]. Additionally, CDK2 promotes HIF-1α transactivation do-
main function, alongside upregulating HIF-1α-mediated expression of downstream target
genes [91]. However, the coupling of HIF-1α to CDK2 presents a dualistic function, whereby
CDK2-cyclin E stimulates HIF-1α degradation through chaperone-mediated autophagy
during the G1/S-phase transition. This, in turn, circumvents the inhibitory effects on DNA
replication elicited through any HIF-1α-MCM interaction. In contrast, CDK1-cyclin B com-
plexes block the lysosomal degradation pathway, a process that promotes HIF-1α protein
stabilisation and target gene activation [91]. Other important cell cycle regulators such
as Aurora B and PLK3 have been shown to directly phosphorylate HIF-1α [92,93]. While
Aurora B promoted ChIP-dependent degradation of HIF-1α [92], PLK3 phosphorylation is
important for the reduced half-life of HIF-1α by an unidentified mechanism [93].
6.2. Cell Cycle Components-Mediated Control of PHDs
PHD1 activity is similarly the subject of cell cycle regulation by the cyclin-dependent
kinases [94]. Ortmann and co-authors (2016) discovered that the serine 130 residue of PHD1
is phosphorylated, but that phosphorylation was dependent upon CDK activity, cell cycle
stage, and specific oncogenic signals. The authors explain that phosphorylation was regu-
lated by the activity of the interphase CDKs (2, 4, and 6), but not CDK1, and by activation of
the proto-oncogenes—Myc and E2F1—both known cell cycle regulators [95,96]. Moreover,
whilst phosphorylation does not functionally alter PHD1 hydroxylase activity in vitro, it
does govern PHD1 target specificity between HIF-1α and Cep192, whereby phosphoryla-
tion increased PHD1 activity toward Cep192 and reduced the interaction with HIF-1α. This
study by Ortmann and co-authors, therefore, establishes a mechanistic link between the cell
cycle and the regulation of PHD1 activity in cells. Cell cycle mediators such as CDKs can
temporally control the activity of PHDs, whereby specific post-translational modifications
(PTMs) can alter their target specificity and direct them to precise targets in response to
cellular signals [94]. PHD1 has further been shown to undergo phosphorylation in response
to JNK2 activation [97]. JNK2 is also a regulator of the cell cycle [98]. Phosphorylation of
serine 74 and serine 162 was detected in breast cancer cells by mass spectrometry. This
phosphorylation was associated with increased PHD1 activity toward HIF-1α. However,
the kinase controlling these modifications was not investigated.
PHD2 is similarly phosphorylated on serine 125, in normoxia, by the mitogen-activated
serine/threonine kinase p70S6K, whereby phosphorylation enhances PHD2-mediated
degradation of HIF-1α [99]. However, in colorectal cancer cells, the PP2A phosphatase and
its regulatory subunit B55α dephosphorylate the serine 125 residue, which reduces PHD2
activity, thereby enhancing HIF-1α accumulation and ultimately stimulating autophagy-
mediated cell survival [99].
More recently, the anaphase promoting complex (APC) activator CDC20 has been
found to mediate the degradation of PHD3 in HCC cells, ultimately increasing the stability
and activity of HIF-1α [100].
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7. Conclusions
As the cell cycle is a process required to replicate the cell’s genome faithfully, therefore,
it follows that mechanisms are in place to integrate stress signals with the cell cycle
machinery (Table 1). In addition, stress pathways such as those induced by hypoxia that
control cell cycle processes should also receive input from the components of the cell cycle.
Additional studies of how 2-OGD enzymes interface with the cell cycle will expand our
knowledge of this important crosstalk between hypoxia and cell cycle signalling pathways.
Table 1. Summary of the interaction between hypoxia and the cell cycle.
Cell Cycle Control Mechanisms in Hypoxia
Transcriptional effects
Hypoxia induces the activation of several transcription factors: HIFs, Myc, p53, AP-1, SP1 and NFκB are all involved in the
transcriptional regulation of cell cycle genes e.g., p27, p21, cyclin D1, A, E.
Myc regulates the expression of cyclins and CDKI. Performs the opposite role of the HIF-α subunits in Myc
transcriptional regulation.
HIF-2α induces cyclin D1 expression.
HIF-1α can both induce or downregulate AURKA expression.
HIF-1α/SMAD3 regulates CDCA2 expression.
NFκB regulates cyclin D1 expression.
NFκB/E2F1 regulates S-phase genes expression.
Transcription-independent effects
HIF-1α interacts with Cdc6, which blocks DNA replication.
PHD1 mediated proline hydroxylation regulates Cep192 and FOXO3A stability as well as DYRK1 activity.
PHD3 mediated proline hydroxylation regulates p53 stability.
PHD2 mediated proline hydroxylation regulates AKT activity.
Regulation of HIFs/PHDs by cell cycle components
CDK1 phosphorylates HIF-1α promoting its stabilization and activity.
CDK2 regulates HIF-1α transactivation activity, while CDK2-cyclin E promotes HIF-1α degradation through autophagy.
Aurora B phosphorylates HIF-1α promoting its degradation.
PLK3 phosphorylates HIF-1α regulating its half-life.
CDK2, 4 and 6 phosphorylate PHD1 at serine 130 regulating its target specificity between HIF-1α and Cep192.
JNK2 regulates the phosphorylation of PHD1 serine 74.
p70S6K phosphorylates PHD2 at serine 125, while is dephosphorylated by the PP2A-B55α phosphatase. This phosphorylation
regulates PHD2 activity.
CDC20 mediates PHD3 degradation, increasing HIF-1α stability and activity.
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Abbreviations
2-OGD 2-oxoglutarate dioxygenases
PHDs (1-3) Prolyl-hydroxylases (isoforms 1-3)
HIF Hypoxia-inducible factor
ODD Oxygen-dependent degradation domain
VHL von Hippel-Lindau protein
RBX1 Ring box protein-1
AP-1 Activator protein 1
Sp1 Specific protein 1
NF-κB Nuclear factor kappa-light chain-enhancer of activated B cells
JmjC Jumonji-C
TET Ten-eleven translocation proteins
DNA Deoxyribonucleic acid
RNA Ribonucleic acid
FTO Fat mass- and obesity-associated protein/alpha-ketoglutarate-dependent
dioxygenase FTP
ALKBH5 Alkylation repair homolog protein 5
ROS Reactive oxygen species
TF Transcription factor
HRE Hypoxia responsive element
MAPK Mitogen-activated protein kinase
G1 Gap 1 phase
S Synthesis phase
G2 Gap 2 phase
M Mitosis
CDK Cyclin-dependent kinases
RCC Renal cell carcinoma
AURKA Aurora Kinase A
HCC Hepatocellular carcinoma
CDCA2 Cell division cycle-associated protein 2
ChIP-Seq Chromatin immunoprecipitation with sequencing
RNA-Seq RNA-sequencing
SMAD3 SMAD family member 3
FIH Factor inhibiting HIF
CAMKII Calmodulin dependent kinase 2
TAK1 Transforming growth factor kinase 1
IκB Inhibitor of nuclear factor kappa B
IKK Inhibitor of nuclear factor kappa B kinase





Cep192 Centrosomal protein 192
SKP1 S-phase kinase-associated protein 1
CDC Cell division cycle protein
FOXO3A Forkhead box O3A
USP9x Ubiquitin specific protease 9 X-linked
USP7-10 Ubiquitin specific protease (7-10)
MCM Minichromosome maintenance protein








SCF Skp-Cullin-F-box containing complex
Egln2 Egl-9 family Hypoxia inducible factor 2
PP2A Protein phosphatase 2
DYRK1 Dual-specificity tyrosine phosphorylation-regulated kinase-1
CMGC Cyclin-dependent (CDK), mitogen-activated protein kinase (MAPK), glycogen
synthase kinases (GSKs) and CDK-like kinases
PLK3 Mammalian Polo-like kinase 3
PTMs Post-translational modifications
JNK2 c-Jun N-terminal kinase 2
APC Anaphase promoting complex
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